Recruiting
Trastuzumab Deruxtecan in Advanced Breast Cancer
To evaluate the efficacy and safety of trastuzumab deruxtecan in advanced breast cancer patients.
ClinicalTrials.gov IDNCT07180264
PhaseNot Applicable
Enrollment118
SponsorWenjin Yin
Age18 Years
SexALL
Conditions studied
Advanced Breast Cancer
About this study
To evaluate the efficacy and safety of trastuzumab deruxtecan in advanced breast cancer patients.
Interventions
- Drug: Trastuzumab deruxtecan — Trastuzumab deruxtecan is a combination of the targeted cancer drug trastuzumab (also known as Herceptin) and a chemotherapy drug called deruxtecan or DXd.
Primary outcomes
- Progression-Free Survival (PFS) (From the date of starting Disitamab vedotin to the date of first documentation of progression or death (up to approximately 1 years))
Eligibility information
Inclusion Criteria:
* Aged ≥18 and older
* Breast cancer patients meeting current guideline recommendations and planning to receive trastuzumab deruxtecan
* ECOG 0-1
Exclusion Criteria:
* During pregnancy and lactation
Study locations
- Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127 China
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.